Allogeneic bone marrow transplantation for acute leukemia in adults

From September 1993 to August 1997, 24 consecutive adult acute leukemia patients (20 AML and 4 ALL) received allogeneic bone marrow transplant (21 sibling, 1 twin, 2 MUD). The probability of 3 year leukemia free survival is 19/24 (79%), the transplant related mortality is 2/24(8%), the relapse rate is 3/24 (13%), The median follow up period is 34 months (range 7-51), Three AML patients with high probability of TRM received a special radiation-free conditioning regimen (mitobronitol/cytarabine/cyclophosphamide) originally described by Kelemen ct al in CML patients for decreasing transplant related complications, All the three patients are alive and disease free over 3 years.